Abstract:Fibrillogenesis of amyloid beta-protein (A beta) has been thought to be implicated in the progression of Alzheimer's disease (AD). Therefore, development of high-efficiency inhibitors is one of the strategies for the prevention and treatment of AD. Serum albumin has been found to capture A beta monomers through its hydrophobic groove and suppress amyloid formation, but the inhibition efficiency is limited. Inspired by the strong inhibition potency of a basic protein, human lysozyme, we have herein proposed to develop a basified serum albumin by converting carboxyl groups into amino groups with ethylenediamine conjugated on the protein surface. The idea was verified with both bovine and human serum albumins (BSA/HSA). Four basified BSA (BSA-B) preparations with amino modification degrees (MDs) from 8.0 to 41.5 were first synthesized. Extensive biophysical and biological analyses revealed that the inhibition potency significantly increased with increasing amino MD. BSA-B of the highest MD (41.5), BSA-B4, which had an isoelectric point of 9.7, presented strong inhibition on A beta(42) fibrillation at a concentration as low as 0.5 mu M, at which it functioned similarly with 25 mu M native BSA to impede 25 mu M A beta fibrillation. Cell viability assays also confirmed that the detoxification of 5 mu M BSA-B4 was superior over 25 mu M native BSA by increasing cell viability from 60.6% to 96.0%. Fluorescence quenching study unveiled the decrease of the binding affinity between A beta(42) and the hydrophobic pocket region of BSA-B4, while quartz crystal microbalance experiments demonstrated that the binding constant of BSA-B4 to A beta(42) increased nearly 5 times. Therefore, the increase of electrostatic interactions between BSA-B4 and A beta(42) was the main reason for its high potency. Hence, aminated BSA achieved a conversion of binding way to A beta from a mainly single-site hydrophobic binding to multiregional electrostatic interactions. Similar results were obtained with basified HSA preparations on inhibiting the amyloid formation and cytotoxicity. This work has thus provided new insights into the development of more efficient protein-based inhibitors against A beta fibrillogenesis.

Amyloid Capture and Aggregation Inhibition by Human Serum Albumin

Multipronged Regulatory Functions of Serum Albumin in Early Stages of Amyloid-β Aggregation

Multifunctionality of Acidulated Serum Albumin on Inhibiting Zn2+-Mediated Amyloid Β-Protein Fibrillogenesis and Cytotoxicity

Quantitation, Visualization, and Monitoring of Conformational Transitions of Human Serum Albumin by A Tetraphenylethene Derivative with Aggregation-Induced Emission Characteristics

Covalent immobilization of human serum albumin on cellulose acetate membrane for scavenging amyloid beta – A stepping extracorporeal strategy for ameliorating Alzheimer's disease

In Search for Low-Molecular-Weight Ligands of Human Serum Albumin That Affect Its Affinity for Monomeric Amyloid β Peptide

Modulation Effect of Acidulated Human Serum Albumin on Cu2+-mediated Amyloid Β-Protein Aggregation and Cytotoxicity under a Mildly Acidic Condition.

Inhibition of toxic metal-alpha synuclein interactions by human serum albumin

Iminodiacetic Acid-Modified Human Serum Albumin: A Multifunctional Agent Against Metal-Associated Amyloid Β-Protein Aggregation and Cytotoxicity.

Insight into the Inhibition Effect of Acidulated Serum Albumin on Amyloid Β-Protein Fibrillogenesis and Cytotoxicity.

Revolutionizing Alzheimer's treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements

Modification of Serum Albumin by High Conversion of Carboxyl to Amino Groups Creates a Potent Inhibitor of Amyloid β-Protein Fibrillogenesis.

Serum Albumin Prevents Protein Aggregation and Amyloid Formation and Retains Chaperone-like Activity in the Presence of Physiological Ligands

Single Chain Fv Antibodies against the 25−35 Aβ Fragment Inhibit Aggregation and Toxicity of Aβ42

Real-Time 3D Imaging and Inhibition Analysis of Human Serum Amyloid A Aggregations Using Quantum Dots

Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42.

Apolipoprotein Serum Amyloid A in Alzheimer's Disease.

HSA Targets Multiple Aβ42 Species and Inhibits the Seeding-Mediated Aggregation and Cytotoxicity of Aβ42 Aggregates

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab